BT Group plc (LON:BT.A) received a GBX 490 ($5.96) target price from Morgan Stanley in a report released on Wednesday.
Several other analysts have also commented on the stock. Shore Capital downgraded AstraZeneca plc to a sell rating and set a GBX 4,000 ($48.92) target price for the company.in a report on Monday, February 6th.
Vodafone Group Plc Gross Margin percentage stands at 25.6% while its Operating Margin for trailing twelve month is 0 percent and Profit margin (ttm) is 0 Percent. Standpoint Research started coverage on shares of Vodafone Group Plc in a research note on Tuesday, January 3rd. They set an "accumulate" rating and a $30.00 target price for the company. The stock gained a consensus recommendation of 2.33 on Zacks Investment Research where the scale runs from 1 to 5, 1 representing Strong buy and 5 showing Strong Sell. The share price of the stock surged 23.48% for the year.
Vodafone Group Plc (NASDAQ:VOD) [Trend Analysis] tries to capture market sentiments, shares raised 0.52% to $25.19. The stock's market cap is GBX 60.21 billion. The stock has a 50-day moving average of $25.24 and a 200 day moving average of $26.96.
"AstraZeneca plc (AZN) Price Target Raised to GBX 5,350 at Jefferies Group LLC" was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another domain, it was stolen and reposted in violation of United States & global copyright and trademark laws. The original version of this piece can be read at https://sportsperspectives.com/2017/03/10/vodafone-group-plc-vod-stock-rating-upgraded-by-goldman-sachs-group-inc.html.
Large investors have recently modified their holdings of the stock.
Vodafone Group Plc (NASDAQ:VOD) Wireless Communications has a Price Earning Ratio of *TBA, which in return shows a value of 34.11 on the Forward PE Ratio. Apriem Advisors now owns 4,428 shares of the cell phone carrier's stock valued at $129,000 after buying an additional 279 shares during the last quarter. Causeway Capital Management LLC increased its stake in shares of Vodafone Group Plc by 0.4% in the second quarter. Apriem Advisors increased its stake in shares of Vodafone Group Plc by 6.7% in the third quarter. JPMorgan Chase & Co. reaffirmed a neutral rating and set a GBX 390 ($4.77) price objective (down previously from GBX 440 ($5.38)) on shares of BT Group plc in a report on Wednesday, November 30th. Finally, Genovese Burford & Brothers Wealth & Retirement Plan Management LLC increased its stake in shares of Vodafone Group Plc by 2,240.9% in the fourth quarter. 2,059,505 shares of the company's stock were exchanged.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company's business is organized into two geographic regions: Europe, and Africa, Middle East and Asia Pacific (AMAP). The Company's segments include UK, Western Europe, DCH and Northern Europe, Central Europe and Italy, and Plastics.